Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.56 |
| ▸ | MERTK | Q12866 | 10/20 | 0.55 |
| ▸ | AXL | P30530 | 9/20 | 0.55 |
| ▸ | FYN | P06241 | 2/20 | 0.53 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.49 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14059343 | 0.82 | PRKCI (0.73) | IKBKETBK1PRKCI | |
| SCHEMBL18617159 | 0.79 | AXL (0.55) | PIK3C3MERTKAXLIKBKETBK1 | |
| SCHEMBL3460917 | 0.78 | PIK3CD (0.67) | — | |
| SCHEMBL3462249 | 0.76 | MERTK (0.46) | PIK3C3MERTKAXL | |
| SCHEMBL3460979 | 0.74 | PIK3CD (0.61) | — | |
| SCHEMBL24838534 | 0.73 | AXL (0.73) | MERTKAXL | |
| SCHEMBL18616311 | 0.73 | PIK3C3 (0.57) | PIK3C3MERTKAXLIKBKETBK1 | |
| SCHEMBL14061611 | 0.73 | PRKCI (0.73) | IKBKETBK1PRKCI | |
| SCHEMBL18615818 | 0.73 | PIK3C3 (0.56) | PIK3C3MERTKAXLIKBKETBK1 | |
| SCHEMBL4682526 | 0.73 | PRKCI (0.67) | IKBKETBK1PRKCICDK8CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| EP-1501514-A4 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1501514-A2 | PROTEIN KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003093297-A2 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211709-A1 | Protein kinase modulators and methods of use | GRK2, MAP4K2, MAPKAPK2 | PIK3C3 875/4885MERTK 833/4885AXL 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.